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Abstract
The Nottingham Prognostic Index Plus (NPI1) is a clinical decision making tool in breast cancer (BC) that aims to
provide improved patient outcome stratification superior to the traditional NPI. This study aimed to validate the
NPI1 in an independent series of BC. Eight hundred and eighty five primary early stage BC cases from Edinburgh
were semi-quantitatively assessed for 10 biomarkers [Estrogen Receptor (ER), Progesterone Receptor (PgR), cyto-
keratin (CK) 5/6, CK7/8, epidermal growth factor receptor (EGFR), HER2, HER3, HER4, p53, and Mucin 1] using
immunohistochemistry and classified into biological classes by fuzzy logic-derived algorithms previously devel-
oped in the Nottingham series. Subsequently, NPI1 Prognostic Groups (PGs) were assigned for each class using
bespoke NPI-like formulae, previously developed in each NPI1 biological class of the Nottingham series, utilising
clinicopathological parameters: number of positive nodes, pathological tumour size, stage, tubule formation,
nuclear pleomorphism and mitotic counts. Biological classes and PGs were compared between the Edinburgh and
Nottingham series using Cramer’s V and their role in patient outcome prediction using Kaplan–Meier curves and
tested using Log Rank. The NPI1 biomarker panel classified the Edinburgh series into seven biological classes sim-
ilar to the Nottingham series (p> 0.01). The biological classes were significantly associated with patient outcome
(p< 0.001). PGs were comparable in predicting patient outcome between series in Luminal A, Basal p53 altered,
HER21/ER1 tumours (p> 0.01). The good PGs were similarly validated in Luminal B, Basal p53 normal, HER21/
ER2 tumours and the poor PG in the Luminal N class (p> 0.01). Due to small patient numbers assigned to the
remaining PGs, Luminal N, Luminal B, Basal p53 normal and HER21/ER2 classes could not be validated. This
study demonstrates the reproducibility of NPI1 and confirmed its prognostic value in an independent cohort of
primary BC. Further validation in large randomised controlled trial material is warranted.
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Introduction
Breast cancer (BC), is one of the leading causes of
death in women but it represents a very heterogene-
ous group of tumours in terms of genotype, pheno-
type, behaviour and response to treatment. With the
number of available treatment options, making the
most appropriate treatment choice is increasingly dif-
ficult and complex and, therefore, a more personal-
ised management of BC is required. However,
clinical decision making in personalised BC treat-
ment requires robust and accurate risk stratification
based on outcome prediction and biology [1].
Personalised treatment plans for BC require inte-
gration of clinical, histopathological and biological
information to effectively stratify patients with regard
to their expected outcome and response to the various
applicable treatment options. There has been increas-
ing interest in use of multigene assays, such as Onco-
type DX
VR
[2] and MammaPrint
VR
[3], and their
potential clinical utility in BC management. How-
ever, the incorporation of molecular taxonomy of BC
using gene expression profiling into routine clinical
decision-making has not proved entirely successful
due to factors including reproducibility, validation,
cost and lack of utility for all BC patients.
The current Nottingham Prognostic Index (NPI)
[4–6] is based on a combination of histopathological
factors (tumour size, lymph node stage and tumour
grading) integrated in a prognostic index formula [7]
which can be used to stratify BC patients with opera-
ble early stage primary BC into prognostic groups.
The utility of the NPI has been confirmed after long-
term follow-up [4], validated independently in large
multi-centre studies [5,8,9], revised to stratify
patients into additional prognostic groups [10], and is
currently adopted in clinical practice in the UK and
other parts of Europe and Australia. However, the
NPI does not reflect the biological heterogeneity of
BC and assigns equal weighting of the prognostic
factors histological grade, tumour lymph node stage
and tumour size to all cancers. It, therefore, requires
further enhancement to support more accurate per-
sonalised management of BC patients.
It is now recognised that the biological characteris-
tics of BC are important for clinical management and
addition of biological markers to the NPI can signifi-
cantly improve risk stratification of BC patients [11].
We have, therefore, developed the Nottingham Prog-
nostic Index Plus (NPI1) [11] which conceptually
evolved to modernise the historical NPI by applying
the prognostic methods used in the NPI, which are
based on well-established powerful clinicopathologi-
cal variables, following BC molecular class assign-
ment. NPI1 is thus based on a two tier evaluation;
the initial assessment determines the biological class
of the tumour (detailed below) and is subsequently
followed by classification using traditional clinicopa-
thological prognostic variables using a tailored
(bespoke) NPI-like prognostic formulae for each bio-
logical class [11–14]. NPI1 uses routine clinical
samples and commonplace laboratory methods and
could integrate easily into current international clini-
cal practice. It has potential clinical utility by provid-
ing improved patient outcome stratification and by
providing a decision making tool which can identify
patients likely to have a good outcome following
conventional BC treatment and a subgroup(s) of
patients at risk of adverse outcome, that is, who are
at increased risk of treatment failure and who could
potentially benefit from additional/alternative therapy,
should these currently be available or become avail-
able in the future [11]. Seven core BC NPI1 Biolog-
ical Classes are initially determined by the evaluation
of 10 BC-related biomarkers using immunohisto-
chemistry and a fuzzy rule induction algorithm [15]
to classify the breast tumours. The molecular classes
identified based on the combination of these 10 bio-
markers using fuzzy logic are similar in biomarker
profile to those intrinsic classes identified using gene
expression profiling and include three luminal classes
(Luminal A, N and B), two basal classes (Basal –
p53 altered and Basal – p53 normal) and two
HER21 classes (HER21/ER1 and HER21/ER2)
[15]. These distinct biological classes of BC showed
significant association with patient outcome [12–14].
Each NPI1 Biological Class is subsequently strati-
fied using a set of well-defined prognostic clinicopa-
thological variables which are combined in bespoke
formulae to stratify each individual NPI1 Biological
Class into two or more prognostic subgroups (NPI1
Prognostic Groups) which have been been shown to
be superior to the classic NPI [11].
In this study, we aimed to validate the NPI1 in a
large independent series of clinically annotated early
stage BCs from a single centre (Edinburgh, UK) to
assess the potential of NPI1 as a prognostic tool in BC.
Materials and methods
Nottingham series
A series of 1073 patients from the Nottingham-
Tenovus Primary Breast Carcinoma Series, aged 70
years or less, presenting with primary operable
(stages I, II and IIIa) invasive BC between 1986 and
1998 were previously used to develop the NPI1
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[11–14]. This is a well-characterised consecutive
series of patients who were uniformly treated accord-
ing to locally agreed clinical protocols [12,16]. All
tumours were less than 5-cm diameter on clinical/
pre-operative measurement and/or on operative his-
tology (T1 and T2). Women aged over 70 years were
not included because of the increased confounding
factor of death from other causes and because pri-
mary treatment protocols for these patients often dif-
fered from those for younger women. Adjuvant
systemic therapies were offered according to the NPI
[2] and hormone receptor (HR) status [2,10]. Patients
in the Moderate I group (NPI 3.41–4.4) with HR-
positive tumours were offered hormonal therapy.
Patients in the Moderate II (NPI 4.41–5.4) and Poor
(NPI 5.41) groups received hormone therapy for
HR-positive tumours and cytotoxic therapy [classical
cyclophosphamide, methotrexate and 5-fluorouracil
(CMF)] for HR-negative tumours if the patient was
fit enough to tolerate chemotherapy. Hormonal ther-
apy was given to 396 patients (40.3%) and chemo-
therapy to 192 (18.9%). A total of 19 patients (1.9%)
in the Moderate II or Poor prognostic groups
received a combination of chemotherapy and endo-
crine therapy (Table 1). Data relating to survival
were collated in a prospective manner for those
patients presenting after 1989 only.
Edinburgh series
The Edinburgh series comprised a cohort of 885
patients treated by breast conservation surgery,
Table 1. Pathological characteristics of the Nottingham and Edinburgh series
Nottingham (n5 1073) n (%) Edinburgh (n5 885) n (%) p-value
Grade
1 158 (14.7) 194 (22.0)
2 348 (32.4) 359 (40.8) <0.001
3 567 (52.8) 327 (37.2)
Tubule formation
1 53 (5.0) 73 (8.3)
2 346 (33.0) 222 (25.3) 0.002
3 651 (62.0) 582 (66.4)
Pleomorphism
1 19 (1.8) 3 (0.3)
2 378 (36.1) 346 (39.5) 0.121
3 651 (62.1) 528 (60.2)
Mitosis
1 349 (33.2) 523 (59.6)
2 190 (18.1) 138 (15.7) <0.001
3 511 (47.6) 216 (24.6)
Size
0.13–10 cm (median 2.0 cm) 0.4–7.0 cm (median 1.7 cm)
<1.5 cm 240 (22.4) 285 (33.6) <0.001
1.5 cm 833 (77.6) 564 (66.4)
Stage
1 654 (61.0) 614 (69.4)
2 330 (30.8) 211 (23.8) 0.014
3 88 (8.2) 60 (6.8)
Nottingham prognostic index
Excellent 110 (10.3) 137 (15.5)
Good 200 (18.6) 251 (28.4)
Moderate 1 293 (27.3) 248 (28.0)
Moderate 2 277 (25.8) 178 (20.1) <0.001
Poor 140 (13.0) 53 (6.0)
Very poor 45 (4.2) 17 (1.9)
Treatment
None 410 (40.3) 95 (10.7)
Chemotherapy 192 (18.9) 118 (13.3) <0.001
Endocrine therapy 396 (38.9) 581 (65.6)
Chemotherapy/endocrine therapy 19 (1.9) 91 (10.3)
Survival
0.4–25.7 years (median 14.3 years) 0.2–25.5 years (median 11.4 years)
Alive 582 (54.2) 584 (66.0)
BC-specific deaths 328 (30.1) 179 (20.2) <0.001
Non-BC-related deaths or lost to follow-up 163 (15.2) 122 (13.8)
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axillary node sampling or clearance and whole breast
radiotherapy between 1981 and 1998 in Edinburgh
(Edinburgh Breast Conservation Series) [17]. Patients
were those considered suitable for breast-conserving
therapy and were T1 or T2, N0 or N1 and M0 for
conventional tumour node metastasis staging. Patients
with larger primary tumours and those with multi-
focal cancers on preoperative assessment were not
considered eligible for inclusion. Standard surgical
treatment was wide local excision. Patients with
tumours measuring >2 cm in diameter and/or clini-
cally N1 received a Level III axillary clearance. For
tumours measuring clinically 2 cm, a lower axillary
node sample (minimum four nodes) was undertaken.
Post-operative breast radiotherapy was given at a
dose of 45 Gy in 20 daily fractions in patients with
one or more pathologically involved node on an axil-
lary node sample; the peripheral lymphatics were
also irradiated over 4 weeks. Patients received adju-
vant systemic therapy as follows: endocrine therapy
(primarily using tamoxifen), chemotherapy alone
(primarily using CMF), chemotherapy plus endocrine
therapy or no adjuvant systemic therapy (primarily
those with grade 1 tumours).
Breast cancer-specific survival (BCSS) is defined
as the interval between the operation and death from
BC, death being scored as an event, and patients who
died from other causes or were still alive were cen-
sored at the time of last follow-up.
This study was approved by the Nottingham
Research Ethics Committee 2 under the title Devel-
opment of a molecular genetic classification of breast
cancer’.
Determination of NPI1 biological class
Immunohistochemical reactivity for the NPI1 bio-
markers in the Nottingham series was previously
determined using standard immunohistochemical
techniques on tumour samples prepared as tissue
microarrays (TMAs) [12]. TMAs for both cohorts
were prepared using 0.6-mm cores. For the Notting-
ham series, one TMA core from the centre and one
from the periphery of the most representative areas
of tumour were included [12]. For the Edinburgh
series, one TMA core per patient from representative
tumour areas was used [18]. The NPI1 was devel-
oped using the following biomarkers: Estrogen
Receptor (ER), Progesterone Receptor (PgR), cyto-
keratin (CK) 5/6, CK7/8 (using the anti-cytokeratin
CAM5.2 clone), epidermal growth factor receptor
(EGFR; HER1), c-erbB2 (HER2), c-erbB3 (HER3),
c-erbB4 (HER4), p53 and Mucin 1 [14]. TMAs of
the Edinburgh series were also stained for these same
biomarkers in Nottingham using the same procedures
as previously described (Supporting Information
Table 1) [12,14]. A series of BC, prepared as TMAs,
with differing levels of expression of the 10 bio-
markers (ranging from negative to strongly positive)
were included as positive and negative controls and
to standardise immunoreactivity. Levels of immuno-
histochemical reactivity were determined by micro-
scopic analysis using the modified Histochemical
score (H-score), giving a semi-quantitative assess-
ment of both the intensity of staining (0–3) and the
percentage of positive cells (0–100) (multiplied to
give values between 0 and 300) [19,20]. Immunohis-
tochemical staining and subsequent scoring, con-
ducted by at least two independent scorers, was
performed in the Nottingham laboratory. For HER2,
the American Society of Clinical Oncology/College
of American Pathologists Guidelines Recommenda-
tions for HER2 Testing in BC were used for assess-
ment [21]. In the Nottingham series, equivocal (21)
HER21 cases were confirmed by chromogenic in
situ hybridisation as previously described [22]. The
Reporting Recommendations for Tumour Marker
Prognostic Studies (REMARK) criteria, recom-
mended by [23], were followed. In the Edinburgh
series, equivocal cases (n5 67) were excluded from
analysis.
For biological classification, a fuzzy logic rule-
based method algorithm was used where the cut-offs
for each biomarker were previously determined [15].
In particular, the median value of markers was used
for ER, PgR, CK7/8, HER3, HER4 and MUC1. The
expertise values were used for those markers that had
a median equal to zero and for those where clinicians
were sure about the value to consider (CK5/6, EGFR,
p53 and HER2). Pathological characteristics of the
885 cases, along with the Nottingham cases, are sum-
marised in Table 1. Hormonal therapy was given to
581 patients (65.6%), chemotherapy to 118 (13.3%)
and 91 patients (10.3%) received a combination of
chemotherapy and endocrine therapy (Table 1).
Determination of NPI1 prognostic groups
The NPI1 Prognostic Groups were then calculated
using bespoke NPI-like formulae, previously devel-
oped in each NPI1 Biological Class of the Notting-
ham series, utilising the existing available
clinicopathological parameters (Table 2) [11].
Briefly, these were established by utilisation of the
Beta values generated by Cox regression analysis in
predicting BCSS of the well-established histopatho-
logic prognostic factors. These formulae were ini-
tially derived from the Biological Classes in Green
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et al 2013 [14] and were subsequently refined using
the improved biological classification used in Soria
et al 2013 [15] consisting of: number of positive
nodes, nodal ratio, pathological tumour size, stage,
tubule formation, nuclear pleomorphism and mitotic
counts. These were identified as the most significant
variables in the Nottingham series impacting on sur-
vival, according to their Beta value in Cox regression
indicating the magnitude of the influence of the haz-
ard. The Nottingham series was split into the NPI1
Biological Classes and Cox regression analyses were
performed independently for each class to identify
the most significant clinicopathological prognostic
factors and their beta value in the context of the indi-
vidual classes. NPI1 Prognostic Groups for the Edin-
burgh series were assigned using the categorical
cutpoints previously derived from the Nottingham
series in each of the NPI1 Biological Classes [11].
For this purpose, the original pathology assessments
on full-face sections for the histopathological param-
eters were utilised.
Statistical analysis
The association between NPI1 Biological Classes and
both histopathological and clinical characteristics was
assessed using Cramer’s V [24]. BCSS between NPI1
Biological classes and NPI1 Prognostic Groups was
determined using Kaplan–Meier curves and tested
using Log Rank. A p< 0.01 was considered signifi-
cant with Bonferroni adjustment for multiple testing.
Results
Clinicopathological parameters of the Edinburgh
series
There were significant differences in the distribution
of grade and size (both p< 0.001) of the breast
tumours between the Nottingham and Edinburgh
series with a larger proportion of the Nottingham
series being of larger tumour size, and of higher
grade and stage (Table 1). The median follow-up for
the Nottingham series was 14.3 years and the Edin-
burgh series was 11.4 years. A total of 328 (36.0%)
and 179 (20.2%) patients died due to their disease in
the Nottingham and Edinburgh series, respectively.
The Edinburgh series had better BCSS (82.1%) over
the first 10-year period compared with the Notting-
ham series (74.7%).
NPI1 biological class
NPI1 Biological Class was determined in the Edin-
burgh series using the immunohistochemical data for
the 10 NPI1 Biomarkers: this showed that there was
a similar distribution between each of the seven
NPI1 Biological Classes (Luminal A, Luminal N,
Luminal B, Basal p53 altered, Basal p53 normal,
HER21/ER1 and HER21/ER2) compared with the
Nottingham series (p5 0.629, Table 3). A total of 51
cases (5.8%) were not assigned to any class com-
pared with 3.5% in the Nottingham series. There
were significant associations between the clinicopa-
thological parameters of the Edinburgh series and the
NPI1 Biological Classes which are summarised in
Table 4. The NPI1 Biological Classes were signifi-
cantly associated with patient survival where the
Luminal and Basal classes had a better BCSS than
the HER21 classes (Figure 1).
NPI1 prognostic groups
There were a similar number of NPI1 Prognostic
Groups evident in each of the biological classes in
the Edinburgh series compared with the Nottingham
series, however, there was a significant difference in
the distribution of the NPI1 Prognostic Groups
between the Nottingham and Edinburgh series (Table
5, p< 0.001) [11]. Some of the poor NPI1 Prognos-
tic Groups were under-represented in the Edinburgh
series due to the relatively lower frequency of highly
proliferative tumours in the series (Table 1) which
may also explain the better survival of this series.
Table 2. NPI1 formulae for the biological classes
Class NPI1 formula
Luminal A (0.8 3 Mitosis)1 (0.5 x Size)1
(1.8 3 Nodal ratio*)
Luminal N (0.8 3 Tubules)1 (0.6 3 Stage)
Luminal B (0.7 3 Mitosis)1 (1.0 3 Nodal ratio)
Basal p53 altered (1.4 3 Nodal ratio)1 (0.4 3 Size)
Basal p53 normal (0.6 3 Stage)1 (1.8 3 Pleomorphism)
HER21/ER1 (0.5 3 Size)1 (0.9 3 Stage)
HER21/ER2 (0.9 3 Stage)2 (0.6 3 Nodal ratio)
*Number of nodes positive/Total number of nodes.
Table 3. Distribution of NPI1 biological classes within the Not-
tingham and Edinburgh series
NPI1 Class
Nottingham
(n5 1073)
n (%)
Edinburgh
(n5 885)
n (%) p-value
Luminal A 288 (26.8) 225 (29.3)
Luminal N 205 (19.1) 152 (19.8)
Luminal B 186 (17.3) 140 (18.3)
Basal p53 altered 113 (10.5) 93 (12.1) p5 0.629
Basal p53 normal 96 (8.9) 70 (9.1)
HER21/ER1 62 (5.8) 32 (3.6)
HER21/ER2 85 (7.9) 55 (6.2)
Unclassified 38 (3.5) 51 (5.8)
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Comparison of the BCSS in each of the NPI1 Prog-
nostic Groups between the Nottingham and Edinburgh
Series showed there were no significant differences in
patient outcome in the majority of NPI1 Prognostic
Groups (Figure 2). Luminal A tumours, which had good
representation in all three NPI1 Prognostic Groups,
showed comparable patient outcome between the Edin-
burgh and Nottingham Series, as did the BCSS of the
Basal p53 altered and HER21/ER1 tumours. Certain
Table 5. Distribution of the NPI1 Groups in the Nottingham
and Edinburgh series
NPI1 group Nottingham n (%) Edinburgh n (%)
Luminal A
1.1 148 (17.9) 160 (21.2)
1.2 83 (10.0) 53 (7.0)
1.3 25 (3.0) 9 (1.2)
Luminal N
2.1 133 (16.1) 151 (20.0)
2.2 17 (2.1) 1 (0.1)
Luminal B
3.1 77 (9.3) 133 (17.6)
3.2 58 (7.0) 3 (0.4)
Basal – p53 altered
4.1 86 (10.4) 78 (10.3)
4.2 10 (1.2) 13 (1.7)
Basal – p53 normal
5.1 44 (5.3) 2 (0.2)
5.2 28 (3.4) 68 (9.0)
HER21/ER1
6.1 31 (3.7) 15 (1.8)
6.2 25 (3.0) 17 (2.1)
HER21/ER2
7.1 55 (6.6) 53 (6.4)
7.2 8 (1.0) 0
Figure 1. BCSS of the Edinburgh series with respect to NPI1
Biological Classes.
Table 4. Clinicopathological parameters of the NPI1 BC biological classes in the Edinburgh series
Luminal A
(n5 219)
n (%)
Luminal N
(n5 144)
n (%)
Luminal B
(n5 137)
n (%)
Basal – p53
altered (n5 90)
n (%)
Basal – p53
normal
(n5 64) n (%)
HER21/ER1
(n5 32)
n (%)
HER21/ER2
(n5 55)
n (%)
Cramer’s V
(p-value)
Size
<15 mm 89 (40.6) 67 (46.5) 50 (36.5) 12 (13.3) 18 (28.1) 7 (23.3) 11 (21.2) 0.169 (<0.001)
15 mm 130 (59.4) 77 (53.5) 87 (63.5) 78 (86.7) 46 (71.9) 23 (76.7) 41 (78.8)
Grade
1 75 (33.6) 47 (30.9) 35 (25.0) 1 (1.1) 3 (4.4) 3 (9.7) 1 (1.8)
2 108 (48.4) 73 (48.0) 72 (51.4) 10 (10.8) 23 (33.8) 8 (25.8) 23 (41.8) 0.381 (<0.001)
3 40 (17.9) 32 (21.1) 33 (23.6) 82 (88.2) 42 (61.8) 20 (64.5) 31 (56.4)
Lymph node stage
1 172 (76.4) 108 (71.1) 100 (71.4) 68 (73.1) 50 (71.4) 15 (46.9) 31 (56.4)
2 44 (19.6) 40 (26.3) 36 (25.7) 18 (19.4) 18 (25.7) 10 (31.2) 15 (27.3) 0.169 (<0.001)
3 9 (4.0) 4 (2.6) 4 (2.9) 7 (7.5) 2 (2.9) 7 (21.9) 9 (16.4)
NPI
Excellent 55 (24.8) 33 (21.9) 23 (16.4) 0 1 (1.5) 2 (6.2) 0
Good 82 (36.9) 54 (35.8) 53 (37.9) 5 (5.4) 15 (22.1) 5 (15.6) 11 (20.0)
Moderate 1 52 (23.4) 34 (22.5) 37 (26.4) 39 (41.9) 29 (42.6) 7 (21.9) 17 (30.9)
Moderate 2 22 (9.9) 26 (17.2) 21 (15.0) 37 (39.8) 19 (27.9) 10 (31.2) 16 (29.1) 0.221 (<0.001)
Poor 11 (5.0) 4 (2.6) 4 (2.9) 8 (8.6) 4 (5.9) 6 (18.8) 8 (14.5)
Very poor 0 0 2 (1.4) 4 (4.3) 0 2 (6.2) 3 (5.5)
Adjuvant therapy
Chemotherapy 5 (2.2) 12 (7.9) 4 (2.9) 25 (26.9) 21 (30.0) 6 (18.8) 16 (29.1)
Hormone therapy 185 (82.2) 100 (65.8) 112 (80.0) 42 (45.2) 32 (45.7) 19 (59.4) 26 (47.3)
Hormone therapy/chemotherapy 14 (6.2) 21 (13.8) 11 (7.9) 10 (10.8) 6 (8.6) 4 (12.5) 6 (10.9) 0.230 (<0.001)
No therapy 21 (9.3) 19 (12.5) 13 (9.3) 16 (17.2) 11 (15.7) 3 (9.4) 7 (12.7)
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NPI1 Groups (Luminal N Group 1; Luminal B Group
2; Basal p53 normal Group 2; HER21/ER2 Group)
could not be compared due to being under-represented
in the Edinburgh series.
Discussion
We have developed the NPI1 methodology with a
view to increasing the information available to
clinicians and patients to allow them to offer more
personalised choices of adjuvant therapy in all early
stage forms of BC. NPI1 was developed on a series
of over 1000 BC cases from a single centre (Notting-
ham, UK) with long-term follow-up [11–14]. We have
previously demonstrated proof-of-principle evidence of
its clinical relevance [11–14]. We have, therefore,
sought to validate and confirm the prognostic capabil-
ities of NPI1 in a large independent series of BC
from a separate centre (Edinburgh, UK).
Although there was some difference in the overall
distribution of size, stage and grade of tumours between
Figure 2. Patient outcome for the NPI1 Prognostic Groups, comparing the Nottingham and Edinburgh series.
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the Nottingham and Edinburgh series, the distribution
of the NPI1 Biological Classes (Luminal A, Luminal
N, Luminal B, Basal p53 altered, Basal p53 normal,
HER21/ER1, HER21/ER2) was similar. This is con-
sistent with the proportion of cancer subtypes reported
in other studies [3,12,14,25–32] and provides evidence
that the classification of BC into seven biological
classes using a discrete panel of 10 proteins assessed by
immunohistochemistry is similar between series.
The second evaluation phase of NPI1 uses well-
established powerful clinicopathological variables to
stratify each of the NPI1 Biological Classes into
clinically distinct subgroups (NPI1 Prognostic
Groups) using bespoke NPI-like formulae. In all
classes, a patient group with a better long-term out-
come was identified which would align with clinical
expectation after use of appropriate adjuvant therapy.
In the Nottingham series in all seven classes, one or
more subgroups of patients were identified who had
an adverse long-term outcome. These latter group(s)
of patients are potential candidates for additional/
alternative forms of therapy as conventional BC man-
agement has failed to mitigate against higher than
expected risk of tumour relapse and death from BC.
It is envisaged that NPI1 can stratify patients with
BCs of any biological class type into a category of
expected good outcome following conventional ther-
apy, or one or more categories of adverse outcome
following conventional therapy. We fully appreciate
that the NPI1 has been developed and validated on
archival breast material from patients treated histori-
cally in routine practice with either chemotherapy
and/or hormone therapy and does not include more
contemporary treatments such as trastuzumab. Further
validation of NPI1 in key BC randomised clinical
trials will allow the prediction of disease recurrence
under these certain treatment options.
In the Edinburgh series, the NPI1 Prognostic Groups
showed comparable BCSS in the Edinburgh series
when compared with the Nottingham series in NPI1
Biological Classes: Luminal A, Basal p53 altered and
HER21/ER1. The NPI1 Prognostic Groups with a
better outcome were similarly validated in the NPI1
Biological Classes: Luminal B, Basal p53 normal and
HER21/ER2 along with the poor NPI1 Prognostic
Group in the Luminal N class. However, due to very
small numbers of patients assigned in the Edinburgh
series, the remaining NPI1 Prognostic Groups of bio-
logical classes Luminal N, Luminal B, Basal p53 nor-
mal and HER21/ER2 could not be validated.
In conclusion, this study shows that the distribution
of the NPI1 Biological Classes are similar in an
independent series of primary BC and we can con-
clude that biological class determination using the
NPI1 biomarker methodology is robust between
patient series. We observed similar patterns of patient
outcome in the majority of NPI1 Prognostic Groups
between the Nottingham and Edinburgh series and
can conclude that NPI1 prognostic classification for
these groups (all groups of classes Luminal A, Basal
p53 altered and HER21/ER1, the good NPI1 Prog-
nostic Groups of classes Luminal B, Basal p53 nor-
mal and HER21/ER2 and the poor NPI1
Prognostic Group of the Luminal N class) appears
reproducible. Three of the poor prognostic groups
(Luminal N, Luminal B, Basal p53 normal and
HER21/ER2) were under-represented in the Edin-
burgh series due to a lower frequency of higher grade
tumours and could not be validated in this study.
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